DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Strattera (Atomoxetine Hydrochloride) - Published Studies

 
 



Strattera Related Published Studies

Well-designed clinical trials related to Strattera (Atomoxetine)

Drug-specific laterality effects on frontal lobe activation of atomoxetine and methylphenidate in attention deficit hyperactivity disorder boys during working memory. [2014]

Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial. [2013]

A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions. [2013]

Does atomoxetine improve executive function, inhibitory control, and hyperactivity? Results from a placebo-controlled trial using quantitative measurement technology. [2012]

A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. [2012]

Correlates of alcohol use in adults with ADHD and comorbid alcohol use disorders: exploratory analysis of a placebo-controlled trial of atomoxetine. [2011.12]

Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. [2011.10.21]

Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. [2011.06]

Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. [2011.06]

Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies. [2011.05.11]

Methylphenidate but not atomoxetine or citalopram modulates inhibitory control and response time variability. [2011.05.01]

Neural correlates of error monitoring modulated by atomoxetine in healthy volunteers. [2011.05.01]

Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women. [2011.05]

Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany. [2011.04]

Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine. [2011.04]

A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. [2011.04]

Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. [2011.03]

A comparison of atomoxetine administered as once versus twice daily dosing on the school and home functioning of children with attention-deficit/hyperactivity disorder. [2011.02]

Effect of atomoxetine on executive function impairments in adults with ADHD. [2011.02]

Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine. [2011.01]

Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blind, placebo-controlled trial. [2011]

A double-blind, placebo-controlled study of atomoxetine in young children with ADHD. [2011]

Once-daily treatment with atomoxetine in adults with attention-deficit/hyperactivity disorder: a 24-week, randomized, double-blind, placebo-controlled trial. [2011]

Effect of atomoxetine on executive function impairments in adults with ADHD. [2011]

A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder. [2010.11]

Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder. [2010.11]

Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD. [2010.09]

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. [2010.08.03]

Post hoc analysis: early changes in ADHD-RS items predict longer term response to atomoxetine in pediatric patients. [2010.08]

Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. [2010.06]

Atomoxetine's effect on societal costs in Sweden. [2010.05]

Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. [2010.01.30]

Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. [2010.01]

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. [2010]

Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD. [2010]

Randomized, controlled trial of atomoxetine for attention-deficit/hyperactivity disorder in adolescents with substance use disorder. [2010]

Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. [2010]

Effect of Atomoxetine on Executive Function Impairments in Adults With ADHD. [2009.12.21]

Atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. [2009.12]

Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder. [2009.12]

A randomized controlled trial of atomoxetine in generalized social anxiety disorder. [2009.12]

Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. [2009.12]

Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. [2009.12]

Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. [2009.11]

Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. [2009.10]

Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. [2009.10]

Atomoxetine for freezing of gait in Parkinson disease. [2009.09.15]

Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study. [2009.09]

Once-daily atomoxetine for treating pediatric attention-deficit/hyperactivity disorder: comparison of morning and evening dosing. [2009.09]

A haplotype of the norepinephrine transporter (Net) gene Slc6a2 is associated with clinical response to atomoxetine in attention-deficit hyperactivity disorder (ADHD). [2009.08]

Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial in Russia. [2009.07.01]

Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder. [2009.06]

Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. [2009.05]

Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. [2009.04.01]

A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. [2009.04]

Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in stimulant-naive Swedish children and adolescents. [2009.04]

Comparison of symptomatic versus functional changes in children and adolescents with ADHD during randomized, double-blind treatment with psychostimulants, atomoxetine, or placebo. [2009.03]

Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. [2009.02]

Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. [2009.02]

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. [2009]

Atomoxetine attenuates dextroamphetamine effects in humans. [2009]

Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. [2008.11]

Acute atomoxetine treatment of younger and older children with ADHD: A meta-analysis of tolerability and efficacy. [2008.09.15]

Abuse liability assessment of atomoxetine in a drug-abusing population. [2008.05.01]

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder. [2008.02]

A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. [2008.02]

Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. [2007.11.01]

High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. [2007.09]

Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. [2007.09]

A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder. [2007.08]

Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. [2007.08]

Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. [2007.07]

Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD. [2007.07]

Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. [2007.04]

Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD. [2007.03.01]

Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. [2007.03]

A pilot study of the effects of atomoxetine on driving performance in adults with ADHD. [2007.02]

Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data. [2007.01]

Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine. [2006.12]

Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder. [2006.12]

Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning. [2006.11]

Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. [2006.10]

Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. [2006.04]

Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. [2006.03]

Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder. [2006.03]

A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder. [2006.02]

Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African-American children with ADHD. [2005.10]

Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. [2005.09]

Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. [2005.08]

Emotional dysregulation in adult ADHD and response to atomoxetine. [2005.07.15]

A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. [2005.07]

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents] [2005.05]

Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants. [2005.05]

Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. [2005.03]

Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. [2005.03]

Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. [2004.10]

Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. [2004.07]

Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. [2004.07]

Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. [2004.02]

Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. [2003.01.15]

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. [2002.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014